Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model

Vaccine

Volumn 32, Issue 26, 2014, Pages 3205-3210

  Verhoeven, David ^a   Xu, Qingfu ^a   Pichichero, Michael E ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Infant vaccination; Pneumococcal choline binding protein A; Pneumococcal histidine triad D protein; Pneumolysin; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; STREPTOCOCCUS PNEUMONIAE RECOMBINANT PNEUMOCOCCAL CHOLINE BINDING PROTEIN A VACCINE; STREPTOCOCCUS PNEUMONIAE RECOMBINANT PNEUMOCOCCAL HISTIDINE TRIAD D VACCINE; STREPTOCOCCUS PNEUMONIAE RECOMBINANT PNEUMOLYSIN D1 VACCINE; STREPTOCOCCUS PNEUMONIAE TRIVALENT RECOMBINANT PROTEIN VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INFANT; LETHAL PNEUMONIA; MALE; MOUSE; MURINE MODEL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTECTION; SEROTYPE; SEROTYPE 3; SEROTYPE 6A; VACCINATION;

INFANT VACCINATION; PNEUMOCOCCAL CHOLINE BINDING PROTEIN A; PNEUMOCOCCAL HISTIDINE TRIAD D PROTEIN; PNEUMOLYSIN; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; FEMALE; HYDROLASES; IMMUNOGLOBULIN G; LUNG; MALE; MICE; MICE, INBRED C57BL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RECOMBINANT PROTEINS; SEPSIS; STREPTOLYSINS; VACCINES, CONJUGATE;

EID: 84900389746     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.004     Document Type: Article

References (33)

1. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
2. van Hoek A.J., Andrews N., Waight P.A., George R., Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One 2012, 7:e39150.
3. Moffitt K.L., Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011, 23:407-413.
4. Webster J., Theodoratou E., Nair H., Seong A.C., Zgaga L., Huda T., et al. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. BMC Public Health 2011, 11(Suppl 3):S26.
5. Malley R., Anderson P.W. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Nat Acad Sci USA 2012, 109:3623-3627.
6. Posfay-Barbe K.M., Galetto-Lacour A., Grillet S., Ochs M.M., Brookes R.H., Kraehenbuhl J.D., et al. Immunity to pneumococcal surface proteins in children with community-acquired pneumonia: a distinct pattern of responses to pneumococcal choline-binding protein A. Clin Microbiol Infect 2011, 17:1232-1238.
7. Glover D.T., Hollingshead S.K., Briles D.E. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 2008, 76:2767-2776.
8. Khan M.N., Pichichero M.E. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine 2012, 30:2900-2907.
9. Plumptre C.D., Ogunniyi A.D., Paton J.C. Polyhistidine triad proteins of pathogenic streptococci. Trends Microbiol 2012, 20:485-493.
10. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001, 69:949-958.
11. Beghetto E., Gargano N., Ricci S., Garufi G., Peppoloni S., Montagnani F., et al. Discovery of novel Streptococcus pneumoniae antigens by screening a whole-genome lambda-display library. FEMS Microbiol Lett 2006, 262:14-21.
12. Ogunniyi A.D., Grabowicz M., Briles D.E., Cook J., Paton J.C. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007, 75:350-357.
13. Melin M., Di Paolo E., Tikkanen L., Jarva H., Neyt C., Kayhty H., et al. Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun 2010, 78:2089-2098.
14. Denoel P., Philipp M.T., Doyle L., Martin D., Carletti G., Poolman J.T. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011, 29:5495-5501.
15. Seiberling M., Bologa M., Brookes R., Ochs M., Go K., Neveu D., et al. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine 2012, 30:7455-7460.
16. Kaur R., Casey J.R., Pichichero M.E. Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children. Pediatr Infect Dis J 2011, 30:645-650.
17. Holmlund E., Quiambao B., Ollgren J., Jaakkola T., Neyt C., Poolman J., et al. Antibodies to pneumococcal proteins PhtD CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage. Clin Vaccine Immunol 2009, 16:916-923.
18. Hagerman A., Posfay-Barbe K.M., Grillet S., Ochs M.M., Brookes R.H., Greenberg D., et al. Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia. Clin Microbiol Infect 2012, 18:756-762.
19. Khan M.N., Sharma S.K., Filkins L.M., Pichichero M.E. PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect/Institut Pasteur 2012, 14:1102-1110.
20. Briles D.E., Hollingshead S.K., Paton J.C., Ades E.W., Novak L., van Ginkel F.W., et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 2003, 188:339-348.
21. Tai S.S. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006, 32:139-153.
22. Salha D., Szeto J., Myers L., Claus C., Sheung A., Tang M., et al. Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun 2012, 80:2212-2220.
23. Kirkham L.A., Kerr A.R., Douce G.R., Paterson G.K., Dilts D.A., Liu D.F., et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 2006, 74:586-593.
24. Ogunniyi A.D., Woodrow M.C., Poolman J.T., Paton J.C. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001, 69:5997-6003.
25. Kamtchoua T., Bologa M., Hopfer R., Neveu D., Hu B., Sheng X., et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine 2013, 31:327-333.
26. Hinojosa E., Boyd A.R., Orihuela C.J. Age-associated inflammation and toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia. J Infect Dis 2009, 200:546-554.
27. Ljutic B., Ochs M., Messham B., Ming M., Dookie A., Harper K., et al. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine 2012, 30:2981-2988.
28. Oloo E.O., Yethon J.A., Ochs M.M., Carpick B., Oomen R. Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease. J Biol Chem 2011, 286:12133-12140.
29. +-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence. Infect Immun 2006, 74:1171-1180.
30. Bernatoniene J., Finn A. Advances in pneumococcal vaccines: advantages for infants and children. Drugs 2005, 65:229-255.
31. Shaper M., Hollingshead S.K., Benjamin W.H., Briles D.E. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 2004, 72:5031-5040.
32. Garcia-Suarez Mdel M., Cima-Cabal M.D., Florez N., Garcia P., Cernuda-Cernuda R., Astudillo A., et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to, pneumolysin. Infect Immun 2004, 72:4534-4540.
33. Musher D.M., Phan H.M., Baughn R.E. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 2001, 183:827-830.